Published in Epilepsia on June 01, 1999
The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol (2004) 0.86
Seizure treatment in transplant patients. Curr Treat Options Neurol (2012) 0.84
The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol (2005) 0.75
Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol (2005) 0.75
Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA (1997) 10.23
A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med (2001) 6.53
Status epilepticus. N Engl J Med (1998) 5.52
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Molecular virology and pathogenesis of hepatitis B. Lancet (1993) 3.27
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother (1985) 1.98
Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol (1999) 1.93
Status epilepticus at an urban public hospital in the 1980s. Neurology (1993) 1.90
Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology (1985) 1.90
Acute hepatitis C. Hepatology (2001) 1.82
Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother (1988) 1.73
Prehospital stability of diazepam and lorazepam. Am J Emerg Med (1999) 1.72
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation (1995) 1.67
Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology (2003) 1.55
Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med (2001) 1.55
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg (1998) 1.54
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut (2003) 1.51
Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm (1980) 1.50
Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis (1992) 1.50
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res (1993) 1.49
Hepatic hydrothorax. Semin Liver Dis (1997) 1.48
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen (2000) 1.46
Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet (1998) 1.46
Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem (1986) 1.46
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS (1990) 1.44
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem (1997) 1.39
Pruritus as a symptom of hepatitis C. J Am Acad Dermatol (1994) 1.39
Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology (1977) 1.38
Recombinational repair is critical for survival of Escherichia coli exposed to nitric oxide. J Bacteriol (2001) 1.33
The prehospital treatment of status epilepticus (PHTSE) study: design and methodology. Control Clin Trials (2001) 1.33
Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem (2000) 1.32
Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest (1985) 1.32
Abnormalities of cell volume regulation and their functional consequences. Am J Physiol (1980) 1.30
The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol (2001) 1.30
Pharmacokinetic evaluation of hemodialysis in acute drug overdose. J Pharmacokinet Biopharm (1978) 1.29
Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology (2005) 1.29
Pharmacokinetics of mecillinam in health subjects. Antimicrob Agents Chemother (1980) 1.28
Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology (1979) 1.26
Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem (1996) 1.25
Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest (1997) 1.24
Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother (1988) 1.23
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol (2000) 1.21
Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest (1995) 1.21
Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1982) 1.20
Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res (1996) 1.19
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology (2000) 1.18
Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg (1992) 1.18
Acetaminophen-induced hepatic necrosis and renal failure. JAMA (1971) 1.18
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology (2000) 1.17
Portal and systemic bacteraemia and endotoxaemia in liver disease. Gut (1978) 1.17
Pharmacokinetics of cefamandole using a HPLC assay. J Pharmacokinet Biopharm (1978) 1.15
Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology (1991) 1.15
Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci (1983) 1.15
Human glutathione S-transferases. Semin Liver Dis (1998) 1.13
Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis. Antimicrob Agents Chemother (1984) 1.13
Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology (1998) 1.11
Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol (1994) 1.10
Structural, functional and hybridization studies of the glutathione S-transferases of rat liver. Biochem Pharmacol (1983) 1.10
Localization of a portion of the active site of two rat liver glutathione S-transferases using a photoaffinity label. J Biol Chem (1989) 1.08
Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol (2001) 1.08
Parathyroid hormone inhibition of Na+-H+ antiporter activity in a cultured renal cell line. Am J Physiol (1986) 1.07
Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest (1996) 1.06
Hemodialysis of phenytoin in a uremic patient. Clin Pharmacol Ther (1975) 1.05
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology (1998) 1.05
High-performance liquid chromatographic determination of cefmenoxime (AB-50912) in human plasma and urine. J Chromatogr (1983) 1.05
Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B Biomed Sci Appl (1998) 1.05
Hepatitis C viral infection in liver transplant recipients. Hepatology (1992) 1.04
Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology (2001) 1.03
Hepatitis C virus: quantitation and distribution in liver. J Med Virol (1997) 1.03
Hepatitis C and liver transplantation. Gut (1999) 1.03
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother (2002) 1.03
Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. J Pharmacokinet Biopharm (1982) 1.01
Molecular cloning of gp42, a cell-surface molecule that is selectively induced on rat natural killer cells by interleukin 2: glycolipid membrane anchoring and capacity for transmembrane signaling. J Exp Med (1991) 1.00
Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol (1995) 0.99
Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology (1993) 0.98
Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther (1977) 0.98
Cholestatic hepatitis C in liver allografts. Liver Transpl Surg (1998) 0.97
Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob Agents Chemother (1987) 0.97
Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem (1995) 0.97
Studies of the relationship between the catalytic activity and binding of non-substrate ligands by the glutathione S-transferases. Biochem J (1984) 0.97
Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res (1995) 0.97
Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology (1996) 0.96
Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm (1980) 0.96
Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet (1993) 0.96
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab (1991) 0.95